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Background: Odontogenic myxoma (OM) is a benign, but locally invasive, neoplasm occurring in the jaws.
However, the molecules implicated in its development are unknown. OM as well as Dental Follicle (DF), an
odontogenic tissue surrounding the enamel organ, is derived from ectomesenchymal/mesencyhmal elements. To
identify some protein that could participate in the development of this neoplasm, total proteins from OM were
separated by two-dimensional electrophoresis and the profiles were compared with those obtained from DF, used
as a control.
Results: We identified eight proteins with differential expression; two of them were downregulated and six
upregulated in OM. A spot consistently overexpressed in odontogenic myxoma, with a molecular weight of 44-kDa
and a pI of 3.5 was identified as the orosomucoid 1 protein. Western blot experiments confirmed the
overexpression of this protein in odontogenic myxoma and immunohistochemical assays showed that this protein
was mainly located in the cytoplasm of stellate and spindle-shaped cells of this neoplasm.
Conclusion: Orosomucoid 1, which belongs to a group of acute-phase proteins, may play a role in the modulation
of the immune system and possibly it influences the development of OM.
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Odontogenic Myxoma (OM) is a relatively rare, benign
neoplasm occurring in the jaws. This neoplasm is char-
acterized by the presence of stellate and spindle-shaped
cells embedded in an abundant myxoid or mucoid extra-
cellular matrix. OM represents 3-20% of all odontogenic
tumours and, in most studies, OM is the third most fre-
quent odontogenic tumor [1]. Conservative surgery by
enucleation and curettage is recommended when lesions
of OM are smaller than 3 cm, but a segmental resection
with immediate reconstruction is preferred in patients
affected by bigger tumors [2].
OM as well as Dental Follicle (DF), an odontogenic
tissue surrounding the enamel organ, and the dental pa-
pilla of the developing tooth germ prior to eruption [3],* Correspondence: marodri@cinvestav.mx
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distribution, and reproduction in any mediumis derived from ectomesenchymal/mesencyhmal ele-
ments. Thus, OM could be mimicked by DF and dental
papilla, both containing myxoid areas [4-6]. Indeed, a
pathologist who is not familiar with the histology of a
tooth germ can mistake a myxoid DF for an OM [6].
Up to now there are few studies comparing molecules
of OM with other odontogenic mesenchymal tissues.
Some authors compared the expression of α-SMA, S-100
and vimentin between OM and other mesenchymal tis-
sues [7,8], but not substantial differences were found.
Another study described that the hyaluronic acid concen-
tration in OM is four times higher than that of other gly-
cosaminoglycans, such as chondroitin sulphate, which is
inversely found in mesenchymal tissues from dental pulp,
gingival and periodontal ligament, but not in DF [9]. It
was also reported that 90% of OM cells expressed the
metalloproteinase 2 (MMP-2), while only 10% of the cells
in DF and myxoid dental pulp expressed this protein [10].
These authors also showed an increased expression ofentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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less than 1% of Bcl-2 positive cells in OM [11,12]. Finally,
some works have been focused on the histological changes
that occur in the hyperplastic DF and normal DF of
impacted third molars and their histological association to
OM and the possibilities of misinterpretation as OM
[4,6,13,14].
In recent years, the use of high-throughput genomics
and proteomics has expanded rapidly in biomedical sci-
ence. These technologies have evolved and make pos-
sible several discoveries in clinical cancer research,
including the identification of biomarkers, molecular
classification of tumors, molecular prediction of metas-
tasis, treatment response, and prognosis. Particularly,
the study of the proteome, the collection of all the pro-
teins expressed from specific cells in all isoforms, poly-
morphisms and post-translational modifications [15],
has allowed the detection of new biomarkers in diverse
types of neoplasitic tissues, for example in urinary blad-
der cancer [16], ovarian carcinomas [17], oral squamous
cell carcinoma [18], and lung cancer [19]. However, in
the literature we have not found any previous study
about OM or other odontogenic tumors using this
approach.
To identify some proteins that could participate in the
biological behavior of OM, in this work we used the
proteomic technology based on 2-dimensional electro-
phoresis (2DE) combined with liquid chromatography-
tandem mass spectrometry (LC-MS/MS) for comparing
odontogenic myxoma (neoplastic) versus dental follicle
(normal) tissues. A spot consistently overexpressed in
odontogenic myxoma was identified as the orosomucoid
1 protein, which was located in the cytoplasm of the
tumor cells.
Results
Protein profiles of OM and DF
To identify proteins with differential expression in OM
with respect to DF, the protein extracts from five OM
(Table 1) and five DF samples were analyzed by 2-DE
using a wide range ampholyte pH 3–10 and profiles
were visualized by colloidal Coomassie Blue G-250 stain-
ing. To minimize gel to gel variation, two-dimensional
gels for each sample were realized at least twice. Both,
DF and OM samples showed similar protein profiles,Table 1 Details of cases
Age Sex Location Approximate evolution
35 Female Jaw/posterior 8 Months
25 Female Jaw/posterior 12 Months
16 Female Maxillary/anterior 3 Months
15 Male Jaw/posterior 7 Months
25 Female Jaw/ramus 3-5 yearsincluding more than 100 spots with molecular masses
ranging from >170 to 5 kDa and pI values between 3
and 10 (Figure 1A, B). Several protein spots consistently
displayed significant differences in expression between
OM and DF. Figure 1 shows representative 2-DE of OM
and DF with spots subjected to mass spectrometry and
their identification numbers; the identified spots are
listed in Table 2.
Identification of orosomucoid-1 (ORM1)
One spot that consistently showed significant upregula-
tion in OM was a molecule of approximately 44 kDa
with a pI value around of 3.5 (Figure 1, square). The
results of the data query from the LC-MS/MS analysis
indicated that four mass values of this spot matched
with a human protein called orosomucoid 1 (ORM1), or
alpha 1 acid glycoprotein, with a sequence coverage of
20.3% (Figure 1C).
Expression of ORM1 in Odontogenic Myxoma vs Dental
Follicle
To verify the differential expression of ORM1, which
could play important functional roles in the develop-
ment of OM, we performed Western blot assays on in-
dependent samples of OM and DF with a commercial
monoclonal antibody. This analysis showed that the anti-
body strongly recognized a band of approximately
44 kDa, the expected molecular weight for the ORM1
protein, in all samples of OM analyzed, whereas this
band was detected with minor intensity in samples of
DF (Figure 2). A 42-kDa band with roughly similar in-
tensity was detected in all samples by an anti-actin anti-
body, used as internal control (Figure 2). We performed
densitometric analysis of the bands detected by those
antibodies and the relative expression of ORM1 in a DF
sample was arbitrarily taken as 1. This analysis showed
that compared with DF, OM presented from 4.5- to 15-
fold increased expression of ORM1 (Figure 2). This re-
sult confirmed that ORM1 is highly expressed in OM.
Expression pattern of ORM1 in Odontogenic Myxoma vs
normal Dental Follicle
To determine the in situ expression of ORM1 in the
tumoral mass of OM, we performed an immunohisto-
chemical assay on fourteen OM and ten DF samplesApproximate diameter Symptoms
3 × 2 cm/with expanded cortical Increased volume/asymptomatic
4 × 2 cm/with expanded cortical Increased volume/paresthesia
4 × 5 cm/with expanded cortical Increased volume/asymptomatic
9 × 5 cm/with expanded cortical Increased volume/asymptomatic
4 × 5 cm/with expanded cortical Increased volume/little pain
Figure 1 2DE protein profiles of Odontogenic Myxoma (OM) and Dental Follicle (DF) and identification of ORM1. Proteins from DF and
OM were extracted and separated in 2DE. Then, gels were stained with Colloidal Coomassie Blue G-250. (A) Protein profile of OM. (B) Protein
profile of DF. Proteins differentially expressed between both samples are numbered and one of the spots that consistently showed significant
upregulation in OM is indicated by a frame. Under each gel are shown the magnifications and differential intensity analyses for the spot
indicated by the frame. (C) This spot was excised from gels and subsequently analyzed by LC-MS/MS. This analysis identified this spot as the
orosomucoid 1 protein (ORM1), which amino acid sequence is shown. The peptides identified by LC-MS/MS are underlined.
Table 2 Identification of proteins with differential expression in Odontogenic Myxoma









1 gi|112877 Orosomucoid-1 23497/4.93 182 21% Acute phase with inflammatory and
immunomodulating properties
2 gi|4507677 GRP94 92696/4.76 471 21% Molecular chaperone and cell signalling
3 gi|4507651 Tropomyosin alpha-4 28619/4.67 383 35% Calcium binding and acti-binding
4 gi|4507953 14-3-3 protein 27899/4.73 341 40% Cell signaling, cycle control, apoptosis
and metabolism
5 gi|90108664 Apolipoprotein A-1 28061/5.27 717 57% Lipid transport, metabolism, apoptosis
and autophagy









23438/5.44 143 22% Detoxify endogenous and environmental
substances
8 gi|4502517 Carbonic anhydrase 1 28909/6.59 376 55% Ubiquitous metalloenzyme; bone resorption,
calcification, ion transport, acid–base
transport and metabolic processes
Accession numbers are from the MASCOT database (http://www.matrixscience.com).
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Figure 2 Western blot assays for detection of the ORM 1
protein. Protein extracts from OM and DF samples were separated
by PAGE-SDS and submitted to Western blot assays using antibodies
against ORM1 and against actin, the latter used as an internal
control. Relative intensities of the bands recognized by the
antibodies were documented and analyzed by densitometry. The
relative expression of ORM1 in a DF sample was arbitrary taken as 1.
Figure 3 In situ expression of ORM1 in OM and DF. Tissue sections from
monoclonal antibody against ORM1, then, with a biotinylated antimouse a
reaction products were visualized by the incubation with 3,3´-diaminobenz
microscopy (20X). Insets show magnifications (40X) of the marked areas. Ar
showed contaminant epithelial cells positive for ORM1.
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displayed positive cytoplasmic staining in majority of the
stellate and spindle-shaped cells in all the analyzed sam-
ples (Figure 3A, B), while mesenchymal cells of DF did
not exhibit immunopositivity (Figure 3C, D). In addition,
in both tissues (OM and DF) the endothelial cells of
large and small blood vessels showed ORM1 positivity
(Figure 3A-D). Positivity was also found in contaminant
epithelial cells of DF (Figure 3D).Discussion
The pathogenesis and source of OM is still controversial.
Some authors have proposed an odontogenic origin, par-
ticularly from the dental follicle or from the periodontal
ligament [20,21]. Other authors have suggested that OM
may be the result of a myxoid change in a pre-existing
mesenchymal lesion or that it may represent a degenera-
tive form of odontogenic fibroma [22]. In contrast, some
authors have posed that the OM has a myofibroblastic ori-
gin [23,24]. Nevertheless, in the last years many studies
have compared the biochemical composition, particularlydifferent samples of OM (A, B) and DF (C, D) were incubated with a
ntibody, and finally with the streptavidine/peroxidase complex. The
idine-H2O2 substrate. Finally, samples were analyzed by optic
rows indicate endothelial cells of blood vessels (B-D). Panel D also
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pulp, dental follicles, gingival tissue and periodontal liga-
ment) of a developing tooth [11,25,26]. The results
obtained in the present study showed that the protein pro-
files of OM and DF are very similar; supporting the notion
that OM could originate from DF.
To analyze proteins differentially expressed in OM
and DF we used a proteomic approach based on 2-DE
and peptide mass fingerprint by LC-MS/MS. This prote-
omic analysis revealed the variation of eight proteins
identified (Table 1).
Expression of carbonic anhydrase I (CA I) and gluta-
thione S-transferase (GST) was downregulated in OM.
Carbonic anhydrases catalyze the hydration of carbon di-
oxide and forms bicarbonate. CA I not only enhances
the hydration reaction of CO2, but it also promotes the
combining of bicarbonate with calcium to form the solid
precipitant of calcium carbonate [27], a principal com-
ponent of bones. Although OM is considered a benign
neoplasm, it shows a high potential for bone resorption
[28]. Thus, downregulation of CA I may affect the bal-
ance between bone resorption and apposition. On the
other hand, GSTs are a large family of enzymes that
catalyze the conjugation of reduced glutathione through
a sulfhydryl group to electrophilic sites on a wide variety
of substrates that could lead to the generation of reactive
oxygen species (ROS) [29]. The products of GST cataly-
sis are more water soluble, promoting ROS detoxifica-
tion and thereby protecting tissues from oxidative
damage. Thus, GST could be acting as a caretaker pro-
tein by protecting cells against genome damage induced
by carcinogens and as a tumor-suppressor protein lead-
ing to tumor growth when inactivated [30]. It is, there-
fore, speculative that downexpression of GST in OM
would lead to genome damage accumulation and be fur-
ther injurious to the oral tissue.
A glucose-regulated protein (GRP94), albumin in a
complex with myristic acid and tri-iodobenzoic acid, the
tropomyosin alpha-4, the 14-3-3 protein zeta/delta, the
apolipoprotein A-I, and the orosomucoid-1 protein were
up-regulated in OM. Interestingly, overexpression of
tropomyosin alpha-4 was also detected in esophageal
squamous cell carcinoma [31], although their participa-
tion in tumor development remains to be investigated.
GRPs refer to a set of endoplasmic reticulum (ER) cha-
perones that have multiple functions in maintaining cel-
lular homeostasis [32]. The endoplasmic reticulum stress
pathways and the GRPs have been linked to cancer
growth and drug resistance [33]. GRPs represent novel
markers for cancer progression and chemo-responsive-
ness, as well as targets for cancer therapy. GRP94, also
known as gp96, is the most abundant glycoprotein in
ER and its overexpression associates with cellular
transformation, tumorigenicity and decreased sensitivityto X-rays, whereas suppression of GRP94 sensitizes cells
to etoposide treatment [32].
The 14-3-3 proteins belong to a family consisting of
highly conserved acidic proteins with molecular weights
of 25–30 kDa. They participate in phosphorylation-
dependent protein-protein interactions that control
progression through the cell cycle, initiation and main-
tenance of DNA damage checkpoints, activation of MAP
kinases, prevention of apoptosis and coordination of in-
tegrin signaling and cytoskeletal dynamics [34]. Accu-
mulating evidence now supports the concept that either
an abnormal state of 14-3-3 protein expression, or dysre-
gulation of 14-3-3/client protein interactions, contri-
butes to the development of a large number of human
diseases. In particular, clinical investigations in the field
of oncology have demonstrated a correlation between
upregulated 14-3-3 levels and poor survival of cancer
patients [35].
ApoA-I is the major protein in HDL and plays an im-
portant role in reverse cholesterol transport by extract-
ing cholesterol and phospholipids from peripheral cells
and transferring it to the liver for excretion. In addition
to its antiatherogenic properties, apoA-I also possesses
anti-inflammatory and antioxidant properties [36].
Decreased levels of Apolipoprotein were found in a var-
iety of cancer [37-39], but such as in OM, Apolipopro-
tein A-I was increased in breast cancer and brain
metastases in lung cancer [40,41]. This controversy
about the regulation of ApoA-I in cancer cells needs to
be clarified in future studies.
By proteomics,Western blot and immunohistochem-
ical assays, in the present study we showed that the
ORM1 protein is overexpressed in OM. Interestingly,
the same strategies allowed the identification of
increased levels of ORM1 in urine samples of patients
with urinary bladder cancer [16]. Moreover, increased
levels of ORM1 have been reported in the sera of
patients with different malignant diseases, including
squamous cell carcinoma of head and neck [42-46].
ORM1 belongs to a group of acute-phase proteins
found in plasma. Such proteins undergo dramatic
changes in concentration as a response of the organism
to a disturbance of its homeostasis. These plasmatic pro-
teins constitute a group of serum factors related to dif-
ferent immunological regulator functions and they have
also been associated with tumor development and
growth. However, it is uncertain whether the serum
levels of acute-phase proteins, such as ORM1, increase
as a response of the host to tumor growth or as a conse-
quence of neoplastic cell production.
Human hepatocytes are normally the site of ORM1
production, but endothelial cells and some tumor cells
can also produce it [16,45,47]. Additionally, some studies
have shown that ORM1 is synthesized by lymphocytes,
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the present study the expression of ORM1 in OM was
mainly detected in the cytoplasm of stellate and spindle-
shaped cells. However, this protein was also detected in
the endothelial cells of blood vessels in both OM and
DF tissue samples. It has been reported that ORM1
alone enhances migration but not the proliferation of
human dermal microvascular endothelial cells, but in
the presence of ORM1 and the vascular endothelial
growth factor A (VEGF-A) the endothelial cells are cap-
able to induce the development of endothelial tubes,
suggesting that ORM1 seems to be involved in the regu-
lation of angiogenesis [50]. Irmak et al. [16] proposed
that the highest increase of ORM1 levels in advanced
stages of urinary bladder cancer, which correspond to a
vascularized tumor, could be due in part to the produc-
tion of this protein by the augmented number of endo-
thelial cells of angiogenically active blood vessels. The
pro-angiogenic collaborative property of ORM1 may
possibly occur in OM, but further studies with the asso-
ciation of angiogenic markers and ORM1 in OM are
needed to test this hypothesis.
The presence of ORM1 in odontogenic myxoma also
suggests a possible immunomodulatory function and a
role in the growth and invasion potential of the
tumoral cells. ORM1 is able to inhibit polymorpho-
nuclear neutrophil activation and is considered a nat-
ural anti-inflammatory, anti-neutrophil, anti-complement
and immunomodulatory agent [51]. Thus, the overexpres-
sion of ORM1 in OM may inhibit the immune response,
resulting in an increase of tumor cell proliferation. Alter-
natively, the high expression of ORM1 in OM could rep-
resent a defense mechanism against proliferation and
invasion of the tumor cells, similar to what occurs in
colon cancer cells. In the latter neoplastic cells, the over-
expression of ORM1 results in a reduced colony-forming
capacity, as well as in a decrease of invasion and adhe-
sion, whereas the inhibition of the expression of ORM1
by antisense oligodeoxynucleotides produces an increase
of these events [52]. However, due to the multiple roles
that have been described for ORM1 [51], it is difficult at
this moment to assign just one specific function of this
protein in OM.
On the other hand, ORM1 has very high carbohydrate
content (45%). Glycoproteins contain carbohydrate resi-
dues from less than 1% until 80% of their total molecular
weight and when glycoproteins include more than 4% of
carbohydrates they are often called mucoproteins, because
they have a high viscosity [53]. Macroscopically OM is an
infiltrative mass of mucoid or slimy material, with a high
viscosity. It is a slow growing tumor consisting of an accu-
mulation of mucoid ground substance and, in some
instances this mucoid mass can be infiltrative and destruc-
tive. The presence of ORM1 in OM possibly can justifythe classical mucoid appearance of this tumor. However,
in the immunohistochemical assays we only observed a
cytoplasmic expression of this protein, whereas extracellu-
lar expression was not detected.
Conclusions
Our results showed that protein profiles of OM and DF
are very similar, supporting the hypothesis that OM
could originate from DF. We also identified eight pro-
teins with differential expression between these samples.
By Western blot and immunochemistry we confirmed
the overexpression of the ORM1 protein in OM. This
protein was located in the cytoplasm of stellate and
spindle-shaped cells of OM as well as in the endothelial
cells of large and small blood vessels. The properties and
functions of ORM1 in this tumor are not clear, although
the current evidence suggests possible immunomodula-
tory and/or angiogenic properties of this glycoprotein in
the biological behavior of OM.
Methods
Tissue samples
Tissue samples were provided from the Department of
Maxillofacial Surgery of the Juarez Hospital in Mexico
City. The protocol was approved by the institutional
committee of research and ethics under the registration
number HJM 1996/11.03.08. For proteomics and West-
ern blot analysis a total of five cases of OM diagnosed
during the period between 2009 and 2011 were used in
this work (Table 1), as well as five samples of DF, the lat-
ter used as control tissues. Besides to the samples previ-
ously described, for immunolocalization assays of ORM1
we added nine OM and five DF samples, previously fixed
in 10% neutral formalin and paraffin-embedded, which
were obtained from the service of Maxillofacial Surgery
of the Hospital Juarez de México and from Universidad
de la República (UDELAR) Uruguay.
Tissue preparation
DF were separated from the mineralized tooth or
extracted from alveolar bone in the routine extraction of
the third molars from 16–20 year-old people. Then,
samples were cleaned using physiological solution, intro-
duced to liquid nitrogen and stored at −70°C until use.
OM specimens were removed during surgery, cleaned
with physiological solution, frozen in liquid nitrogen and
stored at −70°C. In addition, paraffin-embedded sections
of eleven OM and five DF samples were examined by
immunohistochemical assays.
Protein extraction
Protein extraction of DF and OM was based on the select-
ive extraction method described by Gorg et al. [54] and
Perez et al. [55] with minor modifications. Briefly, samples
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trogen, mechanically pulverized and suspended (400 mg
tissue/ml) in sample buffer (7 M urea, 2 M tiourea, 4%
CHAPS, 2% IPG buffer, 40 mM DTT) containing
complete™ protease inhibitor cocktail (Roche, Germany).
Then, samples were disrupted by sonication. Insoluble
material was removed by centrifugation (20,000 xg for
5 min at 4°C), and the supernatant was preserved. Add-
itionally, proteins were precipitated with acetone-TCA
and the 2D Clean-Up Kit (Amersham Biosciences, USA).
The precipitate was diluted in rehydration solution (7 M
urea, 2 M thiourea, 2% CHAPS, 0.5%, IPG buffer and
0.1% bromophenol blue) supplemented with 2 mM DTT.
Protein concentration was measured using 2D Quant Kit
(Amersham Biosciences, USA) according to the manufac-
turer’s recommendations.
Two dimensional electrophoresis (2-DE)
Protein extracts suspended in rehydration solution
(250 μl) were used to rehydrate Immobiline Drystrip
Gels, pH 3–10 of 13 cm (GE Healthcare, USA) for 18 h
at room temperature. Electrofocusing was performed in
an Ettan IPGphor 3 Isoelectric Focusing System (GE
Healthcare, USA) at 16–20 kVh for 5 h. Then, the
immobilized pH gradient (IPG) strips were incubated for
10 min in reducing and alkylating 2-DE equilibration
buffer (6 M urea, 75 mM Tris–HCl, pH 8.8, 29.3% gly-
cerol, 2% sodium dodecyl sulfate and 0.1% bromophenol
blue) plus 65 mM DTT and 135 mM iodoacetamide,
successively. For SDS-polyacrylamide gel electrophoresis
(SDS-PAGE), a standard vertical electrophoresis system
was used with 10% polyacrylamyde gels (15 cm× 13 cm)
in a Gibco BRL V16 gel system. Gels were stained with
Colloidal Coomassie Blue G-250 (Bio-Safe Coomassie
Stain, Bio-Rad Laboratories, USA). A digital image of
the gels was obtained using scanning densitometry
(Image Scanner, Amersham Biosciences, USA) and ana-
lyzed with Image Master 2D Platinum software, version
7.0 (GE Healthcare Life Sciences, Switzerland).
Identification of overexpressed proteins in OM
Six spots consistently overexpressed and two underex-
pressed in OM were excised, subjected to in-gel tryptic
digestion and analyzed by LC-MS/MS [56]. Peptide mass
fingerprinting and MS/MS data were searched against
the human genome database using the MASCOT 2.1
program (http://www.matrixscience,com) allowing a
monoisotopic mass tolerance of 1 Da. Methionine oxida-
tion and one missed tryptic cleavage were used during
the database search.
Western blot
Western blot assays were performed as previously
described [57]. Briefly, proteins in rehydration solutionwere separated by 10% SDS-PAGE and transferred to
nitrocellulose membranes. After blocking for 2 h in 5%
nonfat milk in Tris-buffered saline (TBS) containing
0.05% Tween-20, membranes were incubated with a
monoclonal antibody against the orosomucoid 1 protein
(ORM1) (1:5000) (Abcam, UK) and then with an anti-
mouse secondary antibody conjugated to horseradish per-
oxidase (Invitrogen, USA) (1:10,000). As internal control,
samples were probed with antibodies against α-actin
(kindly provided by Dr. Manuel Hernández-Hernández,
CINVESTAV-IPN). Antibody detection was developed by
chemioluminescence (ECL, GE Healthcare Life Sciences,
Switzerland). Relative intensities were documented and
analyzed by densitometry.
Histopathology and Immunohistochemical staining
OM and DF specimens were fixed in 10% buffered forma-
lin and embedded in paraffin. Tissue sections of 2 μm
thick were obtained and stained with hematoxylin and
eosin, under standard procedures. All slides were reviewed
for histopathological classification of odontogenic tumors
according to the recent classification of head and neck
tumors of the World Health Organization [1].
For immunohistochemical studies, tissue sections from
fourteen OM and ten DF samples were treated with 0.1 M
sodium citrate (pH 6.2) and Tween-20 for the unraveling
of the epitopes. Endogenous peroxidases were blocked
with 0.9% hydrogen peroxide, followed by incubation with
1% BSA in PBS for 5 min, in order to eliminate non-
specific binding. Then, samples were incubated with
monoclonal antibodies against ORM1 (1:200), and then
with a biotinylated anti-mouse antibody, and finally with
the streptavidine/peroxidase complex (LSAB+Labeled
streptavid-Biotin, Dako Corporation, USA). The reaction
products were visualized by incubation with 3,3´-diamino-
benzidine-H2O2 as substrate (Dako Corporation, USA).
Sections were counterstained with Mayer´s hematoxylin
solution and visualized by optical microscopy. As a nega-
tive control, PBS was applied to substitute the primary
antibody.
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